0001640334-20-000615.txt : 20200326 0001640334-20-000615.hdr.sgml : 20200326 20200326114724 ACCESSION NUMBER: 0001640334-20-000615 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190730 ITEM INFORMATION: Unregistered Sales of Equity Securities FILED AS OF DATE: 20200326 DATE AS OF CHANGE: 20200326 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GREEN VISION BIOTECHNOLOGY CORP. CENTRAL INDEX KEY: 0001571804 STANDARD INDUSTRIAL CLASSIFICATION: AGRICULTURE CHEMICALS [2870] IRS NUMBER: 981060941 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-55210 FILM NUMBER: 20744908 BUSINESS ADDRESS: STREET 1: 1255 W. RIO SALADO PARKWAY STREET 2: SUITE 215 CITY: TEMPE STATE: AZ ZIP: 85281 BUSINESS PHONE: 7029972267 MAIL ADDRESS: STREET 1: 1255 W. RIO SALADO PARKWAY STREET 2: SUITE 215 CITY: TEMPE STATE: AZ ZIP: 85281 FORMER COMPANY: FORMER CONFORMED NAME: VIBE WIRELESS CORP. DATE OF NAME CHANGE: 20151116 FORMER COMPANY: FORMER CONFORMED NAME: ANYTRANSLATION CORP DATE OF NAME CHANGE: 20130312 8-K 1 gvbt_8k.htm FORM 8-K gvbt_8k.htm

 

 

SECURITIES AND EXCHANGE COMMISSION  

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): July 30, 2019  

 

GREEN VISION BIOTECHNOLOGY CORP.

(Exact name of registrant as specified in its charter)

 

Nevada

 

000-55210

 

98-1060941

(State or other jurisdiction

 

(Commission File Number)

 

(IRS Employer

of Incorporation)

 

Identification Number)

Rooms 1804-06, 18/F., Wing On House,71 Des Voeux Road Central,

Hong Kong SAR, China

(Address of registrant's principal executive offices)

 

+852-94929967

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

None

 

 

 

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨  

 

 

 
 

 

 

ITEM 3.02. UNREGISTERED SALES OF EQUITY SECURITIES

 

On July 30, 2019, Green Vision Biotechnology Corp. (the “Company”) cancelled 89,000,000 shares of common stock, par value $.001 per share, and re-issued them to Able Lead Holdings Limited. The issuance was done pursuant to Section 4(a)(2) of the Securities Act of 1933. as it was a non-public offering.

 

On May 12, 2017, the Company placed the 89,000,000 shares into escrow with Booth Udall Fuller PLC, pending repayment of a loan and discharge of shares of Lutu International by Able Lead Holdings Limited. Full repayment of such was made on February 27, 2019. Therefore, the 89,000,000 shares were returned from escrow and cancelled, Then they were re-issued to Able Lead Holdings Limited.

 

 

 2

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.  

 

  GREEN VISION BIOTECHNOLOGY CORP.
       
Dated: March 26, 2020 By: /s/ William Ching Wan Lam

 

 

 By: William Ching Wan Lam,  
    Chief Executive Officer  
       

 

 

 

 3